Published in Medical Letter on the CDC and FDA, October 5th, 1998
With the trial announced, Vertex is expanding the scope of the VX-497 development program to explore the potential antiviral activity of the compound, in addition to developing it as a drug for autoimmune indications. Vertex next plans to initiate a Phase II clinical trial in psoriasis, an autoimmune disease of the skin.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.